文献速递肿瘤 PET/CT

CXCR4靶向PET/CT改善边缘区淋巴瘤原发分期

Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.
PubMed 文献 · J Nucl Med · 2021-02-12

结果显示CXCR4 PET/CT能正确识别全部有活力MZL患者且优于常规分期(P < 0.001),并显著影响近半数患者的分期结果和约三分之一患者的治疗方案。

要点

  • CXCR4 PET/CT可正确识别全部有活力MZL患者,优于常规分期(P < 0.001)。
  • 加做CXCR4 PET/CT使近半数患者分期改变、约三分之一治疗方案改变。
  • PET引导活检18例中16例证实为MZL,支持CXCR4成像结果可靠。

核心结论

  • CXCR4 PET/CT适用于MZL原发分期,并有望改进现有诊断流程。

研究设计与样本

  • 仅由CXCR4 PET/CT发现的病灶行活检作为参考标准,并与影像结果比较。
  • 评估CXCR4成像对分期结果与治疗方案的影响。

主要发现

  • CXCR4 PET/CT正确识别全部有活力MZL患者,优于常规分期(P < 0.001)。
  • PET引导活检18例中16例证实为MZL。
  • 加做CXCR4 PET/CT使近半数患者分期结果显著改变、约三分之一治疗方案改变(升级n = 7;降级n = 3;治疗改变n = 8;P < 0.03)。

关键数值与推荐

  • 以PET引导活检病理证实为参考标准,18例中16例证实MZL。
  • 分期改变:升级7例、降级3例;治疗改变8例;P < 0.03。

临床怎么用

  • 对新诊断MZL患者,可在常规分期基础上加做CXCR4靶向PET/CT以改善分期准确性。
  • CXCR4 PET/CT检出而常规影像未见的病灶应行活检确认。
  • CXCR4成像结果可影响治疗决策,尤其对分期升级或降级患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET/CT with 18F-FDG is an integral component in the primary staging of most lymphomas. However, its utility is limited in marginal-zone lymphoma (MZL) because of inconsistent 18F-FDG avidity. One diagnostic alternative could be the targeting of C-X-C motif chemokine receptor 4 (CXCR4), shown to be expressed by MZL cells. This study investigated the value of adding CXCR4-directed 68Ga-pentixafor PET/CT to conventional staging. Methods: Twenty-two newly diagnosed MZL patients were staged conventionally and with CXCR4 PET/CT. Lesions identified exclusively by CXCR4 PET/CT were biopsied as the standard of reference and compared with imaging results. The impact of CXCR4-directed imaging on staging results and treatment protocol was assessed. Results: CXCR4 PET/CT correctly identified all patients with viable MZL and was superior to conventional staging (P < 0.001). CXCR4-directed imaging results were validated by confirmation of MZL in 16 of 18 PET-guided biopsy samples. Inclusion of CXCR4 PET/CT in primary staging significantly impacted staging results in almost half of patients and treatment protocols in a third (upstaging, n = 7; downstaging, n = 3; treatment change, n = 8; P < 0.03). Conclusion: CXCR4 PET/CT is a suitable tool in primary staging of MZL and holds the potential to improve existing diagnostic algorithms.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Duell J, Krummenast F, Schirbel A, et al. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. J Nucl Med. 2021. PMID: 33579803. doi:10.2967/jnumed.120.257279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。